


Pennant Group, Inc. (PNTG)

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001766400

Pennant Group, Inc. PNTG; healthcare	
Grade	D A B C D E fourth fifth of 371 graded peers percentile 72.2; sampling error 2.5 points; lower is stronger
Rank	268 of 371
Profitability	D percentile 75.3
Solvency	C/D percentile 58.6
Growth and financing	B percentile 32.6
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$968.2M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: short runway, distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$40.33 2026-10-08; market equity \$1.4B
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Feb 21, 2024, D from Mar 21, 2024, D/E from Mar 21, 2025, D from Apr 21, 2025

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

The Pennant Group, Inc. is a leading provider of high-quality healthcare services to patients, residents, and clients of all ages, including the growing senior population, in the United States. We strive to be the provider of choice in the communities we serve through our innovative operating model and unique core values. As of December 31, 2025, we operate in multiple lines of business,

including home health, hospice, and senior living services across Alabama, Arizona, California, Colorado, Georgia, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin and Wyoming.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 75.3						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.3%)	(6.6%)	75.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 58.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		1.45	(0.31)	30.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		1.14x	2.96x	86.5	839	2025-12-31
Growth and financing, sleeve percentile 32.6						
Revenue growth, three-year compound		26.0%	10.0%	24.6	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		6.5%	37.1%	66.0	104	2025-12-31
Asset growth, three years		23.7%	2.1%	18.5	704	2025-12-31
Net share issuance, one year		0.7%	2.5%	21.2	634	2026-02-23

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
263	uniQure N.V. (QURE)	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN)	71.1	D	
265	AbCellera Biologics Inc. (ABCL)	71.4	D	
266	Cumberland Pharmaceuticals Inc. (CPIX)	71.6	D	
267	Bausch & Lomb Corp. (BLCO)	71.9	D	
268	Pennant Group, Inc. (PNTG) <	72.2	D	
269	Bausch Health Companies Inc. (BHC)	72.4	D	
270	3M Co. (MMM)	72.7	D	
271	Elanco Animal Health Inc. (ELAN)	73.0	D	
272	ICU Medical Inc/De (ICUI)	73.2	D	
273	Butterfly Network, Inc. (BFLY)	73.5	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	45.8%	8.0%	74
Distance from 52-week high	(5.0%)	(31.4%)	92
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	2.6%	(1.0%)	68
Book value to price	0.29	0.28	50
Sales to price	0.67	0.31	75
Composite equity issuance, five years	21.2%	20.3%	50
Relative strength against the sector, log excess return	0.16	(0.14)	74

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	65 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	\$9.9M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	\$29.6M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$48.3M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
3	assets	us-gaap:Assets	\$968.2M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
4	assets	us-gaap:Assets	\$679.5M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
5	current assets	us-gaap:AssetsCurrent	\$167.4M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
6	current liabilities	us-gaap:LiabilitiesCurrent	\$147.3M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$86.8M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
8	operating income	us-gaap:OperatingIncomeLoss	\$51.9M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
9	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterests	\$374.3M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
10	liabilities	us-gaap:Liabilities	\$593.9M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
11	operating income	us-gaap:OperatingIncomeLoss	\$25.2M	2023-12-31	2026-02-26	10-K	0001766400-26-000014
12	interest expense	us-gaap:InterestExpense	\$5.9M	2023-12-31	2024-02-28	10-K	0001766400-24-000022
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$947.7M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$695.2M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$544.9M	2023-12-31	2026-02-26	10-K	0001766400-26-000014
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$473.2M	2022-12-31	2025-02-27	10-K	0001766400-25-000024
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12.0M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$39.3M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$9.0M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$33.1M	2023-12-31	2026-02-26	10-K	0001766400-26-000014
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.1M	2023-12-31	2026-02-26	10-K	0001766400-26-000014
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.0M	2022-12-31	2025-02-27	10-K	0001766400-25-000024
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14.2M	2022-12-31	2025-02-27	10-K	0001766400-25-000024
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$8.5M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDistributionsAndMinorityInterest	\$45.5M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
26	income tax	us-gaap:IncomeTaxExpenseBenefit	\$11.9M	2025-12-31	2026-02-26	10-K	0001766400-26-000014
27	current assets	us-gaap:AssetsCurrent	\$122.9M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
28	current liabilities	us-gaap:LiabilitiesCurrent	\$101.7M	2024-12-31	2026-02-26	10-K	0001766400-26-000014
29	assets	us-gaap:Assets	\$539.7M	2023-12-31	2025-02-27	10-K	0001766400-25-000024
30	assets	us-gaap:Assets	\$512.1M	2022-12-31	2024-02-28	10-K	0001766400-24-000022
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	34,663,118	2026-02-23	2026-02-26	10-K	0001766400-26-000014
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	34,429,989	2025-02-24	2025-02-27	10-K	0001766400-25-000024